Pharmacophores: Historical Perspective and Viewpoint from a Medicinal Chemist

Pharmacophores and Pharmacophore Searches

Volumn , Issue , 2006, Pages 1-13

  Wermuth, Camille G ^a  

^a Prestwick Chemical   (France)

Author keywords

Concept of receptors; Functional groups; Historical perspective; Pharmacophore searches; Pharmacophores; Structure activity relationships; Three dimensional approach; Two dimensional pharmacophores; Viewpoint of a medicinal chemist

Indexed keywords

FUNCTIONAL GROUPS;

CONCEPT OF RECEPTORS; HISTORICAL PERSPECTIVE; PHARMACOPHORES; STRUCTURE ACTIVITY RELATIONSHIPS; VIEWPOINT OF A MEDICINAL CHEMIST;

PHARMACODYNAMICS;

EID: 84952896774     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527609164.ch1     Document Type: Chapter

References (39)

1. Wermuth, C.G., Ganellin, C.R., Lind- berg, P., Mitscher, L.A., Glossary of terms used in medicinal chemistry (IU- PAC Recommendations 1997). Annu. Rep. Med. Chem. 1998, 33, 385-395.
2. Evans, B.E., Rittle, K.E., Bock, M.G., Di- Pardo, R.M., Freidinger, R.M., Whitter, W.L., Lundell, G.F., Veber, D.F., Ander- son, P.S., Chang, R.S., Lotti, V. J., Cerno, D. J., Chen, T.B., Kling, P. J., Kunkel, K. A., Springer, J.P., Hirshfield, J., Methods for drug discovery: development of po- tent, selective, orally effective cholecysto- kinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
3. Trainor, G., Privileged structures-an update. Annu.Rep. Med. Chem. 2000, 35, 289-298.
4. Sheridan, R.P., Miller, M.D., A method for visualizing recurrent topological sub- structures in sets of active molecules. J. Chem. Inf. Comput. Sci. 1998, 38, 915-924.
5. Thompson, L.A., Ellman, J.A., Synthesis and applications of small molecule li- braries. Chem. Rev. 1966, 96, 555-600.
6. Wermuth, C.G., Search for new lead compounds: the example of the chemical and pharmacological dissection of ami- nopyridazines. J. Heterocycl. Chem., 1998, 35, 1091-1100.
7. Hajduk, P. J., Bures, M., Praestgaard, J., Fesik, S.W., Privileged molecules for protein binding identified from NMR- based screening. J. Med. Chem. 2000, 43, 3443-3447.
8. Parascandola, J., To bond or not to bond. Bull. Hist. Chem. 2003, 28.
9. Earles, M.P., Early theories of the mode of action of drugs and poisons. Ann. Sci. 1961 (publ. 1963), 17, 97-110.
10. Boyle, R., Of the Reconcileableness of Specific Medicines to the Corpuscular Philosophy. Samuel Smith, London, 1685, pp. 72-75.
11. Fränkel, S., Die Arzneimittel-Synthese auf Grundlage der Beziehungen zwischen che- mischem Aufbau und Wirkung. Julius Springer, Berlin, 1901, pp. 13-41.
12. Cushny, A.R., The pharmacologic action of drugs: is it determined by chemical structure or by physical characters? J. Am. Med. Assoc. 1903, 41, 1252-1253.
13. Langley, J.N., On the physiology of the salivary secretion. Part II. On the mutual antagonism of atropin and pilocarpin, having especial reference to their rela- tions in the sub-maxillary gland of the cat. J. Physiol. 1878, 1, 339-369.
14. Langley, J.N., On the reaction of cells and nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J. Phys- iol. 1905, 33, 374-413.
15. Ehrlich, P., Morgenroth, J., über Hae- molysine. Dritte Mitteilung. Berl. Klin. Wochnschr. 1900, 37, 453-457.
16. Maehle, A.H., Prull, C.R., Halliwell, R.F., The emergence of the drug recep- tor theory. Nat. Rev. Drug Discov. 2002, 1, 637-641.
17. Albert, A., Selective Toxicity. The Physico- chemical Basis of Therapy. Chapman and Hall, London, 1979,p.23
18. Fischer, E., Einfluss der Konfiguration auf die Wirkung der Enzyme. Ber. Dtsch. Chem. Ges. 1894, 27, 2985-2993.
19. Woods, D.D., The relation of p-amino- benzoic acid to the mechanism of the ac- tion of sulphonamide. Br. J. Exp. Pathol. 1940, 21, 74-90.
20. Woods, D.D., Fildes, P., The anti-sulpha- nilamide activity (in vitro)of p-aminoben- zoic acid and related compounds. Chem. Ind. 1940, 59, 133-134.
21. Dodds, E.C., Lawson, W., Molecular structure in relation to oestrogenic activ- ity. Compounds without phenanthrene nucleus. Proc. R. Soc. London, Ser. B 1938, 125, 122-132.
22. Schueler, F.W., Sex hormonal action and chemical constitution. Science 1946, 103, 221-223.
23. Easson, L.H., Stedman, E., Studies on the relationship between chemical con- stitution and physiological action. V. Mo- lecular dissymmetry and physiological activity. Biochem. J. 1933, 27, 1257-1266.
24. Beckett, A.H., Stereochemical factors in biological activity. In Fortschritte der Arz- neimittel Forschung, Birkhäuser Verlag, Basel, 1959, pp. 455-530.
25. Farmer, P.S., Ariëns, E. J., Speculations on the design of nonpeptide peptidomi- metics. Trends Pharmacol. Sci. 1982, 3, 362-365.
26. Anden, N.E., Corrodi, H., Fuxe, K., Hoekfelt, B., Hoekfelt, T., Rydin, C., Svensson, T., Evidence for a central nor- adrenaline receptor stimulation by cloni- dine. Life Sci. 1970, 9, 513-523.
27. Barlow, R.B., Introduction to Chemical Pharmacology, 2nd edn. Methuen, Lon- don, 1964.
28. Belleau, B., An analysis of drug-receptor interactions. In Modern Concepts in the Relationship Between Structure and Phar- macological Activity, Brunings, K. J. (ed.). Pergamon Press, Oxford, 1963, pp. 75-99.
29. Pullmann, B., Coubeils, J.L., Courrière, P., Gervois, J.P., Quantum mechanical study of the conformational properties of phenethylamines of biochemical and medicinal interest. J. Med. Chem. 1972, 15, 17-23.
30. Wermuth, C.G., Schwartz, J., Leclerc, G., Garnier, J.P., Rouot, B., Conformation de la clonidine et hypothèses sur son inter- action avec un récepteur alpha-adrénergi- que. Chim. Thér. 1973, 1, 115-116.
31. Marshall, G.R., Binding-site modeling of unknown receptors. In 3D QSAR in Drug Design, Theory Methods and Applica- tions, Kubinyi, H. (ed.). ESCOM, Leiden, 1993, pp. 80-116.
32. Wermuth, C.G., Langer, T., Pharmaco- phore identification. In 3D QSAR in Drug Design. Theory Methods and Applica- tions, Kubinyi, H. (ed.). ESCOM, Leiden, 1993, pp. 117-136.
33. Wermuth, C.G., The impact of QSAR and CADD methods in drug design. In Rational Approaches to Drug Design, Hoeltje, H.D., Sippl, W. (eds.). Prous Science, Barcelona, 2001, pp. 3-20.
34. Schneider, G., Giller, T., Neidhart, W., Schmid, G., "Scaffold-hopping" by topo- logical pharmacophore search: a contri- bution to virtual screening. Angew. Chem. Int. Ed. 1999, 38, 2894-2896.
35. Rognan, D., Boulanger, T., Hoffmann, R., Vercauteren, D.P., André, J.M., Durant, F., Wermuth, C.G., Structure and molec- ular modeling of GABAA antagonists. J. Med. Chem. 1992, 35, 1969-1977.
36. Ariëns, E. J., Rodrigues de Miranda, J.F., Simonis, A.M., The pharmacon-recep- tor-effector concept: a basis for under- standing the transmission of informa- tion in biological systems. In The Recep- tors, O'Brien, R.D. (ed.). Plenum Press, New York, 1979, pp. 33-91.
37. Wermuth, C.G., Aminopyridazines-an alternative route to potent muscarinic agonists with no cholinergic syndrome. Farmaco 1993, 48, 253-274.
38. Rognan, D., Sokoloff, P., Mann, A., Mar- tres, M.P., Schwartz, J.C., Costentin, J., Wermuth, C.G., Optically active benza- mides as predictive tools for mapping the dopamine D2 receptor. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 1990, 3, 59-70.
39. Morphy, R., Kay, C., Rankovic, Z., From magic bullets to designed multiple ligands. Drug Discov. Today 2004, 9, 641- 651.